Silverback Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Public
  • Employees
  • 83
Employees
  • Stock Symbol
  • SBTX
Stock Symbol
  • Share Price
  • $3.76
  • (As of Monday Closing)

Silverback Therapeutics General Information

Description

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Contact Information

Website
www.silverbacktx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 500 Fairview Avenue North
  • Suite 600
  • Seattle, WA 98109
  • United States
+1 (206) 000-0000

Silverback Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Silverback Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.76 $3.95 $3.70 - $63.41 $139M 35.1M 332K -$3.26

Silverback Therapeutics Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV (7,289) 1,691,029
Revenue 0 0 0 0
EBITDA (78,393) (32,281) (23,523) (17,142)
Net Income (79,103) (32,947) (23,967) (17,579)
Total Assets 352,561 394,804 15,647 27,547
Total Debt 6,170 4,066 15,620 7,734
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Silverback Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Silverback Therapeutics‘s full profile, request access.

Request a free trial

Silverback Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Silverback Therapeutics‘s full profile, request access.

Request a free trial

Silverback Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its Immu
Biotechnology
Seattle, WA
83 As of 2021
00000
0000 0000-00-00
00000000 00000

0000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000 000000000
San Diego, CA
00 As of 0000
00000
000000000 00000

0000000

eprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000 000000000
Boston, MA
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Silverback Therapeutics Competitors (49)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioAtla Formerly VC-backed San Diego, CA 00 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 49 competitors. Get the full list »

Silverback Therapeutics Patents

  • 54

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 13

    Pending

  • 000

    Expiring in next 12 mo

Silverback Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210275683-A1 Nectin-4 antibody conjugates and uses thereof Pending 21-Feb-2020 00000000000
US-20210130473-A1 Tgfßr1 inhibitor-asgr antibody conjugates and uses thereof Pending 09-Oct-2019 00000000000
US-20210077632-A1 Formulations of benzazepine conjugates and uses thereof Pending 15-Aug-2019 00000000000
US-20210139477-A1 Alk5 inhibitors, conjugates, and uses thereof Pending 16-Jul-2019 0000000000
CA-3131104-A1 Cyclic amino-pyrazinecarboxamide compounds and uses thereof Pending 06-Mar-2019 C07D401/12
To view Silverback Therapeutics’s complete patent history, request access »

Silverback Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
Laura Shawver Ph.D Chief Executive Officer & Board Member
Valerie Odegard Ph.D President & Chief Scientific Officer
Jonathan Piazza Chief Financial Officer, Finance
Peter Thompson MD Co-Founder & Chairman
Peter Baum Vice President, Immunology
You’re viewing 5 of 10 executive team members. Get the full list »

Silverback Therapeutics Board Members (11)

Name Representing Role Since
Andrew Powell JD Self Board Member 000 0000
Jonathan Root MD US Venture Partners Board Member 000 0000
Laura Shawver Ph.D Silverback Therapeutics Chief Executive Officer & Board Member 000 0000
Maria Koehler Ph.D Self Board Member 000 0000
Melissa McCracken Ph.D Nextech Invest Board Observer 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Silverback Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Silverback Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Silverback Therapeutics‘s full profile, request access.

Request a free trial